
STAT News
Moderna and Merck cancer vaccine reduces melanoma recurrence risk by 42% in trial
Detailed trial data confirm that a personalized mRNA cancer vaccine developed jointly by Moderna and Merck reduced the risk of disease recurrence in melanoma patients by 42% compared to standard treatment. The vaccine met its key endpoints in the trial.





















